Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash

Nat Rev Neurol. 2014 Jun;10(6):311-3. doi: 10.1038/nrneurol.2014.82. Epub 2014 May 20.

Authors

Martin Stangel¹, Olaf Stüve²

Affiliations

¹ Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.
² Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Centre, 4500 South Lancaster Road, Dallas, TX 75216, USA.

PMID: 24840971
DOI: 10.1038/nrneurol.2014.82

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Drug Substitution / methods*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Male
Multiple Sclerosis / drug therapy*
Propylene Glycols / therapeutic use*
Sphingosine / analogs & derivatives*

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Propylene Glycols
Sphingosine